WO2009116944A1 - Use of a substance for manufacturing of a medicament for treatment of common cold - Google Patents

Use of a substance for manufacturing of a medicament for treatment of common cold Download PDF

Info

Publication number
WO2009116944A1
WO2009116944A1 PCT/SE2009/050291 SE2009050291W WO2009116944A1 WO 2009116944 A1 WO2009116944 A1 WO 2009116944A1 SE 2009050291 W SE2009050291 W SE 2009050291W WO 2009116944 A1 WO2009116944 A1 WO 2009116944A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxidase
hydrogen peroxide
medicament
producing enzyme
peroxide producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2009/050291
Other languages
English (en)
French (fr)
Inventor
Krister Tano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES09721305T priority Critical patent/ES2436037T3/es
Priority to US12/933,438 priority patent/US8895282B2/en
Priority to DK09721305.2T priority patent/DK2276505T3/da
Priority to CN2009801100377A priority patent/CN101977625A/zh
Priority to PL09721305T priority patent/PL2276505T3/pl
Priority to EP09721305.2A priority patent/EP2276505B1/en
Priority to JP2011500740A priority patent/JP5558458B2/ja
Publication of WO2009116944A1 publication Critical patent/WO2009116944A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to treatment and/or prevention of a disease caused by rhino viruses.
  • the hydrogen peroxide also contributes as a substrate for lactoperoxidase (LPO), a member of the non-specific defence system of the nasopharyngeal mucosa. Lactoperoxidase is dependent of hydrogen peroxide for production of hypothiocyanate, OSCN " , a more potent antibacterial substance.
  • the normal bacterial flora including AHS and the human mucosa have a natural protection against both hydrogen peroxide and hypothiocyanate [2].
  • EP 1 490 096 disclose the use of a hydrogen peroxide producing nasal spray for treatment of otitis media, preferably in children.
  • otitis media preferably in children.
  • Rhinovirus While there are several antibiotics intended to treat otitis media, there is no proved active treatment against the common cold caused by Rhinovirus.
  • One embodiment of the present invention is related to a method for treatment and/or prevention of a disease, caused by a Rhino virus, wherein a patient in need is treated with a medicament comprising a hydrogen peroxide producing enzyme.
  • the hydrogen peroxide producing enzyme is selected from the group consisting of: Glucose oxidase, xylitol oxidase, mannitol oxidase, lactate oxidase, galactose oxidase and glycerol oxidase.
  • the hydrogen peroxide producing enzyme is glucose oxidase combined with amyloglucosidase.
  • the disease is the common cold.
  • the hydrogen peroxide producing enzyme is formulated in Ringer's solution.
  • the medicament is water soluble.
  • the medicament is formulated as a nasal spray.
  • the medicament is formulated as nose drops.
  • an enzyme substrate is added to the medicament.
  • Rhino viruses are the most common agent causing common cold [3]. Furthermore, otitis media in children are often preceded by a common cold. RV is not a systemic infection, but is located in the nasal cavity and in the nasopharynx [4]. It is known that hydrogen peroxide can inactivate RV [5], but it is not possible to make a nasal spray comprising hydrogen peroxide in order to inactivate a RV infection due to several reasons: a. Nasal distribution of a spray does not involve the posterior parts of the nasal cavity, where most of the viral particles are situated [6]. b. The enzyme catalase, which is abundant in the mucosal cells, would convert hydrogen peroxide into water and oxygen long before it would reach the posterior nasal area. c. A sufficient hydrogen peroxide concentration would have to be high initially, and would therefore cause considerable irritation of the nasal mucosa [7].
  • a hydrogen peroxide producing enzyme to permanently inactivate Rhinoviruses. It has been demonstrated that an incubation of only 30 minutes is sufficient to inactivate a considerable amount (>100 TCID50) of a Rhino virus inoculate in human tracheal cells.
  • Glucose oxidase is a hydrogen peroxide producing enzyme, well tolerated for human use. Is is a natural ingredient in honey [8] and it has been used for many years as an antibacterial preservative. The hydrogen producing effect of GO has also been used as an antibacterial additive in different mouth rinses (Oral BalanceTM) and in toothpaste (ZendiumTM).
  • Amyloglucosidase is an enzyme that produces glucose from starch and has its optimal effect at a temperature around 50-60°C. GO and AGO are sometimes combined in order to prevent the activation of GO at lower temperatures. When the solution meets the body temperature, AGO will start to release glucose and GO will produce hydrogen peroxide. Otherwise it would be necessary to use a two-chamber system in order to avoid the mixing of the enzyme (GO) and the substrate (glucose).
  • Suitable substrates for nasal use would for example be: xylitol (having an antibacterial effect in itself), mannitol (an adhesive effect against certain otitis media pathogens), lactate (innate substance), galactose, glycerol (good for the nasal mucosa) and glucose.
  • xylitol having an antibacterial effect in itself
  • mannitol an adhesive effect against certain otitis media pathogens
  • lactate innate substance
  • galactose glycerol
  • glucose glucose
  • the hydrogen peroxide producing enzyme is glucose oxidase combined with amyloglucosidase.
  • Ringer's solution has a more beneficial effect on the mucociliary system of the nasal mucosa than physiological saline [9]. This could indicate that Ringer's solution is the preferable carrier solution for a pharmaceutical preparation in the nasal cavity.
  • Rhinoviruses (viruses belonging to the genus rhinovirus) is a causative agent for the common cold.
  • a glucose oxidase concentration, producing hydrogen peroxide concentrations of about 0,05% should thus be sufficient in order to mimic the effect in vivo of a normal bacterial flora with a very good inhibitory activity.
  • the experiments below indicate that a GO concentration of less than 20 U/ml have an effect on the Rhinovirus infection, corresponding to a hydrogen peroxide concentration of more than 10 mM.
  • the third example illustrates that a significant reduction of the signs of a common cold is achieved already after 12 hours of treatment.
  • the inventor have used the nasal spray during the last three years during episodes of common cold and the pattern is nearly always the same: After frequent use of the nasal spray with GO, every second hour during the first 12 hours, and after that less frequent (2 - 4 times a day during the following 2-3 days), the symptoms of common cold disappears within 12-24 hours after beginning of the treatment. Also other volunteers have reported the same effects of the spray. These pilot studies show that the presence of GO is at a sufficient level long enough to inactivate the RV situated in the nose and nasopharynx.
  • Catalase quickly transforms hydrogen peroxide into oxygen and water, so it is not likely that it would function with a nasal spray containing hydrogen peroxide, especially as the rhinovirus often is situated on the adenoid in the nasopharynx [5].
  • Catalase is a specific enzyme catalyzing the conversion OfH 2 O 2 into O 2 and H 2 O. This reaction proceeds rapidly. Purified catalase from human erythrocytes (>30 000U/mg) was used in the experiments.
  • the cell culture used in the experiments with the rhino viruses is the recommended WI 38 cell line originating from human fetal lung fibroblasts and with an obvious cytopathic effect (CPE), when incubated together with a rhinovirus.
  • CPE cytopathic effect
  • the objective of the following example is to show the effect of a hydrogen peroxide producing enzyme, glucose oxidase, on rhinoviruses, the cause of common cold.
  • Rhino virus 7 purchased from ATCC (VR-1117), was used as a representative for the rhino virus group. In the assays the dilutions 10 "2 and 10 "3 were used. These concentrations should correlate to 100 TCID50 and produced a clear and massive cytopathogenic effect (CPE) in previous dilution series, when assayed together with WI 38. 0,3 ml of each dilution was added into the vials.
  • CPE cytopathogenic effect
  • Cell culture Human lung cell fibroblasts (WI 38, ATCC - CCL-75) was used for cytopathic effect detection. 10-fold serial dilutions had been made from the concentrated viral suspension. 0,1 ml of a dilution of 10 "4 to 10 "5 was sufficient to produce visible cytopathic effect within 5 days in 2 ml wells. A dilution of 10 "3 or more was enough to destroy the majority of the cells after 5 days of inoculation. The cells were first cultured in RPMI with 10% fetal calf serum until a smooth layer was seen at the bottom of the wells. Then the media was changed to RPMI with 2% of fetal calf serum, which was preserved during the assay. The cells were incubated in CO 2 enriched air at 37 0 C. During the experiments a cell culture of 17 th - 18 th passage was used.
  • Catalase From Sigma- AldrichTM. A solution of 100 000U/ml was prepared from the original solution of 10 6 U/ml. 0.01 ml was added to the vials, which resulted in 1000U/ml in the vials.
  • H 2 O 2 a 20% solution was diluted in Phosphate buffered saline (PBS) to a 0,5% and a 0,05% solution. 0,1 ml was added to the vials, which means 0,05% or 0,005% in the vials.
  • PBS Phosphate buffered saline
  • Glucose Oxidase Rehydrex with 2,5% glucose: 0,6 ml was used in each vial as a substrate for Glucose Oxidase.
  • the WI 38 cells were sensitive to a severe toxic effect of 0,05% H 2 O 2 and a slight toxic effect of the enzyme Glucose Oxidase (GO). However the slight toxic effect of Glucose Oxidase did not prevent the possibility to examine the cells regarding the cytopathic effect of RV 7.
  • the objective of the following example is to evaluate the optimal concentration and dose of a nasal spray containing glucose oxidase in a pilote clinical trial to treat common cold.
  • the test person, K.T. aimed to investigate if a nasal spray containing 100U/ml Glucose Oxidase, together with a nasal spray containing 5% of glucose, could reverse the symptoms of a common cold.
  • the spray was not supposed to be used as a prophylactic, but only after symptoms as rhinitis together with blocked nose and/or sneezing.
  • the symptoms were graded in a scale from 0-5 and at the end of the day the symptoms were re-evaluated with the same scale. For details regarding the protocol see Table 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/SE2009/050291 2008-03-20 2009-03-20 Use of a substance for manufacturing of a medicament for treatment of common cold Ceased WO2009116944A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES09721305T ES2436037T3 (es) 2008-03-20 2009-03-20 Spray nasal o gotas nasales para el tratamiento del resfriado común
US12/933,438 US8895282B2 (en) 2008-03-20 2009-03-20 Use of a substance for manufacturing of a medicament for treatment of common cold
DK09721305.2T DK2276505T3 (da) 2008-03-20 2009-03-20 Næsespray eller næsedråber til behandling af forkølelse
CN2009801100377A CN101977625A (zh) 2008-03-20 2009-03-20 物质在制备治疗感冒药物中的应用
PL09721305T PL2276505T3 (pl) 2008-03-20 2009-03-20 Sprej do nosa lub krople do nosa do leczenia przeziębienia
EP09721305.2A EP2276505B1 (en) 2008-03-20 2009-03-20 Nasal spray or nasal drops for treatment of common cold
JP2011500740A JP5558458B2 (ja) 2008-03-20 2009-03-20 普通感冒の治療用の医薬の製造における物質の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0800658 2008-03-20
SE0800658-7 2008-03-20

Publications (1)

Publication Number Publication Date
WO2009116944A1 true WO2009116944A1 (en) 2009-09-24

Family

ID=41091160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2009/050291 Ceased WO2009116944A1 (en) 2008-03-20 2009-03-20 Use of a substance for manufacturing of a medicament for treatment of common cold

Country Status (8)

Country Link
US (1) US8895282B2 (cg-RX-API-DMAC7.html)
EP (1) EP2276505B1 (cg-RX-API-DMAC7.html)
JP (1) JP5558458B2 (cg-RX-API-DMAC7.html)
CN (1) CN101977625A (cg-RX-API-DMAC7.html)
DK (1) DK2276505T3 (cg-RX-API-DMAC7.html)
ES (1) ES2436037T3 (cg-RX-API-DMAC7.html)
PL (1) PL2276505T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009116944A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11185080B2 (en) 2014-04-30 2021-11-30 Matoke Holdings Limited Antimicrobial compositions
EP3810067A4 (en) * 2018-06-25 2022-04-13 Triumph Pharmaceuticals Inc. METHOD OF INHIBITING MICROBIAL INFECTIONS USING ZINC-CONTAINING COMPOSITIONS
US11730168B2 (en) 2017-10-16 2023-08-22 Matoke Holdings Limited Antimicrobial superabsorbent compositions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213491B2 (en) * 2015-05-19 2019-02-26 The Penn State Research Foundation Glucose oxidase compositions as a neonate anticonvulsant
JPWO2017033616A1 (ja) * 2015-08-21 2018-06-07 森永乳業株式会社 上気道保護剤及び上気道保護用飲食品組成物
EP3522717B1 (en) * 2016-10-06 2024-01-24 Matoke Holdings Limited Antimicrobial compositions
WO2019136168A1 (en) 2018-01-03 2019-07-11 Penn State Research Foundation Glucose oxidase compositions as a neonate anticonvulsant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500387A2 (en) * 1991-02-21 1992-08-26 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora using haloperoxidase
WO1995026137A1 (en) * 1994-03-26 1995-10-05 Knoll Ag Method of killing microorganisms
WO2003080109A1 (en) * 2002-03-22 2003-10-02 Krister Tano Use of hydrogen peroxide producing enzyme for treatment of otitis media
US20060073212A1 (en) * 2004-04-22 2006-04-06 Palmer Craig R Method of treating respiratory disorders and airway inflammation
US20070026085A1 (en) * 2005-07-26 2007-02-01 Global Life Technologies Corp. Antimicrobial and antiviral composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702831L (sv) 1987-07-10 1989-01-11 Ewos Ab Microbicid komposition
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
GB2285218A (en) * 1993-12-17 1995-07-05 William Elwyn Roberts An aid to recovery from disease caused by bacteria fungi viruses and malignant cells
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
KR20010021749A (ko) * 1997-07-11 2001-03-15 추후제출 리노바이러스 감염을 억제하는 산화질소
DE29723959U1 (de) * 1997-07-22 1999-07-22 Zellner, Gerhard, Dr., 83435 Bad Reichenhall Nasenspray-Flüssigkeit
KR20020032591A (ko) 1999-09-17 2002-05-03 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 라이노바이러스 감염에서의 csaid의 용도
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US6214339B1 (en) * 2000-01-12 2001-04-10 Michael A. Pellico Di-enzymatic treatment of outer ear infection in dogs and cats
AR030753A1 (es) 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
CN1408358A (zh) * 2002-09-20 2003-04-09 高艺歌 一种葡萄糖酸锌(胶体)喷鼻剂的处方组成
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
BRPI0617481A2 (pt) 2005-10-21 2011-07-26 Danisco composiÇço que compreende um sistema enzimÁtico acoplado

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500387A2 (en) * 1991-02-21 1992-08-26 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora using haloperoxidase
WO1995026137A1 (en) * 1994-03-26 1995-10-05 Knoll Ag Method of killing microorganisms
WO2003080109A1 (en) * 2002-03-22 2003-10-02 Krister Tano Use of hydrogen peroxide producing enzyme for treatment of otitis media
US20060073212A1 (en) * 2004-04-22 2006-04-06 Palmer Craig R Method of treating respiratory disorders and airway inflammation
US20070026085A1 (en) * 2005-07-26 2007-02-01 Global Life Technologies Corp. Antimicrobial and antiviral composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2276505A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11185080B2 (en) 2014-04-30 2021-11-30 Matoke Holdings Limited Antimicrobial compositions
US11311017B2 (en) 2014-04-30 2022-04-26 Matoke Holdings Limited Antimicrobial compositions
US11730168B2 (en) 2017-10-16 2023-08-22 Matoke Holdings Limited Antimicrobial superabsorbent compositions
US12225905B2 (en) 2017-10-16 2025-02-18 Matoke Holdings Limited Antimicrobial superabsorbent compositions
EP3810067A4 (en) * 2018-06-25 2022-04-13 Triumph Pharmaceuticals Inc. METHOD OF INHIBITING MICROBIAL INFECTIONS USING ZINC-CONTAINING COMPOSITIONS
US12053485B2 (en) 2018-06-25 2024-08-06 Triumph Pharmaceuticals Inc. Methods of inhibiting microbial infections using zinc-containing compositions

Also Published As

Publication number Publication date
EP2276505A4 (en) 2011-06-22
EP2276505B1 (en) 2013-09-18
PL2276505T3 (pl) 2014-01-31
US20110044966A1 (en) 2011-02-24
ES2436037T3 (es) 2013-12-26
JP5558458B2 (ja) 2014-07-23
CN101977625A (zh) 2011-02-16
JP2011515391A (ja) 2011-05-19
US8895282B2 (en) 2014-11-25
DK2276505T3 (da) 2013-11-25
EP2276505A1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
EP2276505B1 (en) Nasal spray or nasal drops for treatment of common cold
US6685937B2 (en) Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
JP3478821B2 (ja) ペルオキシダーゼの予防および治療への応用
EP1007086B1 (en) Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
WO2007053619A2 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
RU2006145899A (ru) Ферменты для фармацевтического применения
KR20090100376A (ko) 귀에서 생물막을 용해시키기 위한 가수분해 및 산화 효소의 용도
CN101505790A (zh) 眼病的治疗
SK91498A3 (en) Nisin in combination with glycerol monolaurate active against helicobacter
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
EP0671943B1 (en) Use of enzymes, especially bromelain, in the treatment of non-infectious diarrhoea
US20020081265A1 (en) Composition for treatment of a bacterial infection of the upper respiratory tract
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
EP2934571A1 (en) Prophylactic treatment of herpes recurrence
CN111991414B (zh) 一种β-壳糖胺在制备预防和治疗新冠肺炎病毒感染的药物中的用途
WO2021228875A1 (en) Treatment of respiratory viral infections
ES2541829T3 (es) Composiciones para el tratamiento de los síntomas asociados con inflamaciones respiratorias
Khalil et al. Povidone Iodine (PVP-I) mouth gargle/nasal spray may be the simplest and cost effective therapeutic antidote for COVID-19 Frontier
US20050238635A1 (en) Use of hyrogen peroxide producting enzyme for treatment of otitis media
ES2761613T3 (es) Barrera biológica con simeticona para su uso en el tratamiento de infecciones nasofaringotubáricas
CN101480385A (zh) 一种蛋氨酸的用途
WO2022161381A1 (zh) 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用
WO2021224836A1 (en) A synergistic formulation for management of respiratory pathogens including coronaviruses
US20230111350A1 (en) Opthalmic Compositions for Treating Coronaviruses
WO2022162254A1 (es) Composición para su uso en forma de gotas nasales y nebulizadores como antiviral

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980110037.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721305

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2011500740

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009721305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12933438

Country of ref document: US